Education
About Us
Working with TipRanks
Follow Us
Aoife Brennan Insider Profile
4 Followers
Aoife Brennan, President & CEO, Director at Synlogic, holds 256.30K shares in Synlogic (Ticker: SYBX), holds ― shares in Ra Pharmaceuticals (Ticker: RARX), holds 27.95K shares in FibroGen (Ticker: FGEN).
Aoife Brennan has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Aoife Brennan holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Aoife Brennan
Aoife Brennan's Trading History
Synlogic
Apr 05, 2023
President & CEO, Director
Uninformative Sell
10.85K
$299.87K
Ra Pharmaceuticals
―
―
―
―
FibroGen
Jun 09, 2023
Director
Uninformative Buy
―
$235.59K
Xilio Therapeutics
―
Director
―
―
Climb Bio
Jul 01, 2025
President & CEO, Director
Uninformative Buy
56.80K
$221.41K
List of latest transactions for each holding click on a transaction to see Aoife Brennan's performance on stock
You May Also Like
Aoife Brennan insider profile FAQ
What is the percentage of profitable transactions made by Aoife Brennan?
The percentage of profitable transactions made by Aoife Brennan is ―.
What is the average return per transaction made by Aoife Brennan?
The average return per transaction made by Aoife Brennan is ―.
What stocks does Aoife Brennan hold?
Aoife Brennan holds: SYBX, RARX, FGEN, XLO, CLYM stocks.
What was Aoife Brennan’s latest transaction?
Aoife Brennan latest transaction was an Uninformative Sell of $10.85K.
What was Aoife Brennan's most profitable transaction?
Aoife Brennan’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Aoife Brennan's role in Synlogic?
Aoife Brennan's role in Synlogic is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.